Gain Therapeutics CFO to resign, CEO to serve as interim finance chief
Gianluca Fuggetta is stepping down as principal financial officer, and Gene Mack will take on the CFO role in addition to his CEO duties starting October 1, 2026.
SEC filing
Latest
2 stories
Monday, September 28
Tuesday, August 11
Gain Therapeutics gets FDA IND clearance for rexaceract, targets Phase 2 start in Q3 2026
The company reported second-quarter 2026 results and said the FDA has completed review of rexaceract's IND application, clearing the way for Phase 2 testing in Parkinson's disease.
SEC filing